# Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

> **NCT00693433** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** dexamethasone
- **DRUG:** temsirolimus
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00693433
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-08
- **Final completion:** —
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2015-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00693433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00693433, "Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00693433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*